Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New method for combating prostate cancer

22.06.2007
A novel method of drug delivery to inhibit the growth of prostate cancer cells has been developed by a doctoral candidate in pharmacy at the Hebrew University of Jerusalem.

The student, Danny Goldstein, received the Barenholz Prize for Creativity and Originality in Applied Research for his work. The award, named for its donor, Yehezkel Barenholz, the Dr. Daniel G. Miller Professor of Cancer Research at the Hebrew University-Hadassah Medical School, was presented recently during the 70th meeting of the Hebrew University’s Board of Governors.

Prostate cancer is the second leading cause of cancer-related death for men in the U.S. Present treatments for metastatic prostate cancer (cancer cells that spread to other parts of the body) include hormonal therapy, chemotherapy and radiotherapy, which frequently have serious side effects.

The well known drug, paclitaxel, exhibits a wide spectrum of anti-tumor activity. However, its therapeutic application in cancer therapy is limited, in part, due to its low water solubility, making it difficult to effectively deliver the drug to the points needed. It is also known to induce hypersensitivity reactions. Therefore, novel methods are needed that would allow for delivery of effective concentrations of paclitaxel over extended time intervals while minimizing toxicity.

Targeting drugs to disseminated prostate metastases is one of the most challenging goals in prostate cancer therapy. Drug carriers -- nanoemulsions, liposomes (fatty droplets) and nanoparticles -- have shown great potential as delivery systems for an increasing number of active molecules. Although capable of enhanced accumulation in the target tissue, these carriers cannot achieve their missions unless specific binding agents are attached to them which will ensure that they succeed in attaching to the targeted tissues.

It has been shown that the HER2 receptor is over-expressed in prostate cancer cells. It was also known that trastuzumab (an antibody) binds specifically to HER2. But there had been no clinical data indicating that this antibody would provide any relief for prostate cancer patients.

Goldstein, a student of Prof. Simon Benita, was able to show that attaching trastuzumab molecules to the surface of oil droplets in nanoemulsions made possible the targeting of such droplets to cells over-expressing the HER2 receptor. He coupled trastuzumab with emulsions containing the toxic agent paclitaxel-palmitate and evaluated the efficiency of these emulsions in laboratory tests on cancerous prostate cells and on mice with induced prostate cancer. He found that this emulsion compound did not cause a hypersensitive reaction upon injection and even yielded better results than known drug treatments while inhibiting tumor growth substantially.

Goldstein cautions that this inhibiting activity of tumor metastases growth was not absolute and that while the results are encouraging, there is a need for further research to combat metastatic prostate cancer. Prof. Benita added that he hopes clinical trials using the new method can begin in about two years.

Jerry Barach | alfa
Further information:
http://www.huji.ac.il

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>